Texas Dupixent Lawsuit Attorneys Handling Claims Nationwide
Pharmaceutical Litigation
Is There a Lawsuit Against Dupixent?
Yes, our Dupixent lawyers are bringing individual lawsuits and will represent victims in any potential class actions. Here’s what you need to know about the early stages:
- Dupixent lawsuits allege the medication may increase the risk of cutaneous T-cell lymphoma (CTCL).
- Drug manufacturers Sanofi and Regeneron failed to warn patients about the potential link between Dupixent use and CTCL development.
- We are taking action on behalf of patients who developed CTCL after taking Dupixent, as well as other conditions, like non-Hodgkin lymphoma.
- Individual cases may be consolidated into multidistrict litigation (MDL). There are no trials or settlements yet.
The medication is widely prescribed. Over a million patients are treated with Dupixent worldwide. It is estimated to have generated around $47.53 billion, and is on track to become one of the highest-grossing pharmaceutical products in history.
What is Dupixent Used For?
This injectable medication, Dupixent (generic name Dupilumab, was developed by manufacturers Sanofi and Regeneron Pharmaceuticals. It was approved by the FDA in 2017 for moderate-to-severe atopic dermatitis (eczema). Dupixent works by blocking two pathways.
The medication later received FDA approval for treating conditions, such as the following:
- Atopic dermatitis (eczema) – adults, adolescents 12-17, children 6-11
- moderate to severe asthma (eosinophilic or oral-steroid dependent)
- Chronic rhinosinusitis with nasal polyps (CRSwNP)
- Eosinophilic esophagitis
- Prurigo nodularis
- Chronic obstructive pulmonary disease (COPD)
It later received FDA approval for other approved uses, including Bullous pemphigoid (BP) and chronic spontaneous urticaria with uncontrolled H1 antihistamines.
What are the Worst Side Effects of Dupixent?
The worst side effects of Dupixent so far include:
- Cutaneous T-cell lymphoma (CTCL)
- Severe allergic reactions (anaphylaxis, angioedema)
- Eosinophilic disease (pneumonia, EGPA, vasculitis)
- Severe eye injury
- Severe joint pain/arthritis
- Blood vessel inflammation (vasculitis)
- Serious infections (including parasitic / helminth)
- High eosinophil counts (eosinophilia)
- Common but less severe (conjunctivitis, dry eye, injection site reactions, colds)
Dupixent CTCL Lawsuit
Scientific Evidence for Dupixent Side Effects: Cancer Risk
Sanofi Genzyme of Sanofi and Regeneron Pharmaceuticals funded several studies. These studies raises concerns over how the dangerous drug was approved by the FDA. The findings by Sanofi Genzyme and drug company-funded studies show
- Phase III study trials note that the generic name dupilumab “provides rapid and sustained efficacy and is generally well tolerated.”
- Atopic dermatitis findings for long-term safety were presented by Sanofi Genzyme, reinforcing that the drug “does not require initial or ongoing blood testing.”
- In pediatric asthma trials (6 to 11 years), the company stated outcomes were “generally safe.”
- In the Phase 3 pediatric trial for eosinophilic esophagitis, safety results were “generally safe.”
- In 24-week prurigo nodularis trials, company-funded researchers indicated consistency with prior safety findings.
| Issue | Description and Support of Dupixent Lawsuit Claims |
|---|---|
| Short durations | Many lasted 16–24 weeks, which is inadequate for long-term risks. |
| Narrow populations | Exclusion of higher-risk patients limits symptoms in real-world applications. |
| Underpowered for rare events | Studies designed to detect only common AEs. |
| Bias in safety interpretation | Press releases emphasize “consistent safety profile” without detailed risk disclosure. |
| No monitoring requirements | Sanofi asserts no need for baseline or ongoing tests. |
| Selective reporting | New research wasn't reported in early studies. |
Hasan Study and Mandel Study are retrospective cohort studies using TriNetX data findings published in the Journal of the American Academy of Dermatology and Dermatologic Therapy, respectively.
- Patients taking Dupixent had a 4x higher risk of developing cutaneous T-cell lymphoma. Those with eczema had 4.6x.
- 62% patients diagnosed within one year of starting Dupixent with cutaneous T-cell lymphoma
- 54% of cancer diagnoses occurred in older adults (over age 60)
- Risk was NOT increased for other cancers like melanoma, basal cell carcinoma, or non-Hodgkin lymphoma
- Dupixent/dupilumab administration accounts for 31% of all CTCL cases linked to any biologic drug. This is more than any other medication
Park Systematic Review published in the International Journal of Dermatology showed:
- Average of 7.8 months after taking Dupixent before a cutaneous T-cell lymphoma cancer diagnosis
- Undiagnosed CTCL resulted in advanced disease (stage III or IV)
MA Study (asthma research) showed:
- 4.5x increased risk of CTCL in asthma patients
- Asthma patients have a 14x higher risk of developing NK-cell or cutaneous T-cell lymphoma
Northwestern University Study published in the Journal of the American Academy of Dermatology showed:
- Patients treated initially improved for about 2 months, then got worse
- 4 were misdiagnosed with eczema but actually had skin cancer
- Those diagnosed with cutaneous T-cell lymphoma worsened with Dupixent/Dupilumab use.
- Warning signs included new rashes, increased itching, swollen lymph nodes, and symptoms affecting both the skin and the body.
FDA Safety Analysis states:
- Dupixent users reported CTCL 30x more often than users of all other medications
- Over 87,000 adverse reactions linked to Dupixent were reported in 2025
- March 2025: The Food and Drug Administration issued a safety alert
- Dupixent may change how the immune system works, possibly accelerating skin cancer development
CTCL Symptoms
Warning signs of undiagnosed CTCL after taking Dupixent include:
- Persistent red or scaly skin patches resembling eczema
- Intense itching or burning not improving with standard treatments
- Rashes, lumps, tumors, discoloration
- Thickened skin on palms and soles
- Swollen lymph nodes
- Hair loss, unexplained weight loss, night sweats, fever
Cutaneous T-cell lymphoma is a rare and aggressive type of skin cancer that develops in white blood cells. It’s a rare cancer. The risk of cutaneous T-cell lymphoma is critical for pending litigation because it’s often misdiagnosed as severe eczema or psoriasis. CTCL symptoms often mimic common skin conditions. Many cases have indicated that Dupixent can worsen hidden lymphomas mistaken for psoriasis or eczema, despite Sanofi and Regeneron Pharmaceuticals failing to adequately warn.
As undiagnosed lymphoma progresses, it can visually cover up to 80% of the skin surface. Additionally, cutaneous T-cell lymphoma can spread to internal organs, including the spleen and liver.
Forms of Cutaneous T-Cell Lymphoma (CTCL) Included in Potential Dupixent CTCL Lawsuit
Forms of cutaneous T-cell lymphoma (CTCL) include:
Mycosis Fungoides
This is the most common type of cutaneous T-cell lymphoma. Mycosis fungoides typically presents with scaly patches or plaques on the skin, according to medical sources.
Sézary Syndrome
Sézary syndrome is another rare but aggressive form of CTCL.
Lymphomatoid Papulosis (LyP)
This is a condition with often-benign chronic papules or nodules that resemble lymphoma.
Primary C-ALCL
Primary cutaneous anaplastic large cell lymphoma generally appears as solitary or localized tumors on the skin.
SPTCL
Subcutaneous panniculitis-like T-cell lymphoma is a rare cancer and CTCL subtype, primarily affecting the skin’s fat layer. It often includes nodules that can mimic panniculitis.
Extranodal NK/T-cell Lymphoma
Extranodal NK/T-cell lymphoma is an aggressive and rare cancer that typically arises outside the lymph nodes, often in the nasal region or other organs.
PCGD-TCL
Primary cutaneous gamma-delta T-cell lymphoma is an aggressive and rare type and fast-growing type of skin cancer that develops from gamma-delta T cells.
PCAECTCL
Primary cutaneous acral CD8+ T-cell lymphoma (PCAECTCL) is a rare type of slow-growing non-Hodgkin lymphoma affecting the hands or feet.
Those using Dupixent face an increased risk of developing CTCL compared to those who don’t. The way the medication was researched may have resulted in a delayed diagnosis for many patients. Early CTCL treatment is crucial. Since the drug manufacturers didn’t provide adequate warnings for the risk of CTCL, development may lead to worsened hidden lymphomas mistaken for eczema. If you developed CTCL or anything listed above, contact a Dupixent lawsuit attorney for a free case review.
Other Dupixent Lymphoma Lawsuit Options
- Non-Hodgkin lymphoma (NHL)
- Hodgkin lymphoma
- Angioimmunoblastic T-cell lymphoma
- Anaplastic large-cell lymphoma
- Non-follicular lymphoma
If you or a loved one suffered from undiagnosed lymphoma and were later diagnosed, contact a Dupixent Lawsuit attorney for a free consultation.
Dupixent Skin Cancer Lawsuit
- Melanoma (including melanoma in situ)
- Squamous cell carcinoma (SCC): Multiple lesions possible
- Basal cell carcinoma (BCC)
Other Dupixent Cancer Lawsuit Options (Solid Tumor)
- Pancreatic cancer
- Glioblastoma multiforme (brain cancer)
- Sinonasal cancer (advanced)
- Prostate cancer/prostatic carcinoma
- Testicular cancer
- Angiosarcoma
Lawsuits For Dupixent Eye Side Effects and Vision Changes
Dupixent / dupilumab therapy is commonly prescribed for eczema, asthma, and other conditions. Recent research suggests eye injuries related to using Dupixent include an increased risk of:
- Ulcerative keratitis / corneal ulceration: This is a serious complication that can lead to blindness.
- Peripheral ulcerative keratitis (PUK): A rare and aggressive type of corneal disease that can destroy eye tissue and cause blindness.
- Cicatrizing conjunctivitis: Progressive scarring that can lead to permanent blindness.
- Punctal stenosis (tear duct obstruction): Causes scarring and narrowing of the tear ducts. It results in chronic tearing and infection risk.
- Irreversible cicatricial keratoconjunctivitis: A severe inflammatory eye disease resulting in permanent blindness. Karger case study
- Uveitis – Inflammation inside the eye.
Drug manufacturers didn’t put this on the warning label. This means doctors, patients, and families weren’t aware of the risks. If you or a loved one developed serious side effects, like eye injuries or vision loss, after being treated with Dupixent, you may be eligible to file a lawsuit. Our Dupixent lawsuit attorneys are investigating individual documented cases nationwide.
Dupixent Lawsuit for Vasculitis, EGPA, and Eosinophilic Pneumonia
While not a primary focus of litigation, patients have also experienced vasculitis, eosinophilic granulomatosis with polyangiitis (EGPA/Churg-Strauss syndrome), and eosinophilic pneumonia. Suppressing the immune system causes reactions or unmasks underlying conditions affecting the lungs, heart, kidneys, and blood vessels.
If you developed one of these conditions, consult our legal team to determine if you qualify to file a Dupixent lawsuit for failure to warn.
Other Dupixent Side Effects Lawsuit Options
While cutaneous T-cell lymphoma is the primary focus of litigation, users who suffered other serious adverse reactions besides cancer risk also may be eligible to file a Dupixent lawsuit.
- Vasculitis (blood vessel inflammation)
- Severe injection site or allergic reactions
- Herpes virus reactivation
- Chronic joint pain and respiratory infections
If you experienced severe side effects requiring medical care, hospitalization, or causing long-term conditions while taking Dupixent, you may be eligible to file an individual lawsuit. Contact our Dupixent lawsuit law firm to discuss your legal options.
Who Qualifies to File A Dupixent Lawsuit?
You may be eligible to file a Dupixent lawsuit if the following apply to you:
- were prescribed Dupixent for eczema, asthma, COPD, or another approved condition
- were diagnosed with cutaneous T-cell lymphoma or had a delayed diagnosis for a condition mentioned after starting Dupixent
- used Dupixent for at least one month
- had no prior lymphoma or leukemia diagnosis before using Dupixent
- have not missed your state’s filing deadlines
- are a family who lost a loved one
Claimants will need the following medical evidence to file a lawsuit:
- Pharmacy records
- Medical records showing you were diagnosed with CTCL or another condition mentioned after starting Dupixent
- Documentation of treatment and ongoing medical care
Dupixent Class Action Lawsuit Status
Dupixent lawsuits are currently being brought individually. Many Dupixent lawyers anticipate potential Multidistrict Litigation (MDL) as documented cases grow. Our Dupixent injury law firm is investigating claims for patients diagnosed with cutaneous T-cell lymphoma, other cancer diagnoses, or other serious conditions.
Primary Dupixent Claims Against The Drug Company
- Manufacturers’ failure to warn patients and healthcare providers about cancer risks, including the CTCL risk
- Negligent testing and safety monitoring before bringing the dangerous drug to consumers
- Dupixent’s warning label understated or omitted serious side effects
- Manufacturers were negligent in how they marketed the medication
A Dupixent class action lawsuit would consolidate claims across the country. This allows patients to seek compensation based on damages, like medical expenses, lost wages, pain and suffering, or families bringing legal action for wrongful death.
If you were harmed by using Dupixent, contact a Dupixent drug injury lawyer for a free case review, as filing deadlines apply.
Dupixent Lawsuit Statute Of Limitations
The statute of limitations is different in every state. Most states allow 2-3 years from diagnosis or discovery of harm. It is critical to consult a Dupixent drug injury lawyer experienced in MDLs.
Potential Dupixent Lawsuit Settlement and Payouts
Financial compensation for dangerous drugs depends on the severity of harm. Our Dupixent drug injury lawyers seek justice and the maximum compensation you deserve for patients harmed. This includes medical costs, such as past and future medical bills (treatment, chemotherapy, hospitalization, surgery), lost wages, pain and suffering, and emotional distress. We’ll also seek compensation for permanent disability or wrongful death when merited. Settlements will vary.
Our Dupixent lawsuit attorneys will also seek damages for gross negligence (punitive) if we can prove manufacturers knowingly concealed cancer risks.
Dupixent Lawsuit FAQs
Is Dupixent Safe?
Dupixent is FDA-approved but carries serious risks. The FDA issued a warning letter in March 2025. Recent studies show an increased risk of CTCL, Sezary Syndrome, and other serious side effects.
Can Dupixent Cause Cancer?
Potentially. Drug users have a 4x increased risk of developing CTCL compared to control groups. 62% of skin cancer cases occurred within the first year of treatment. The FDA found Dupixent users reported this 30x more often than other drugs.
Can Dupixent Cause Lymphoma?
Yes. Dupixent is linked to lymphoma, including mycosis fungoides and Sézary syndrome. For t-cell lymphoma, Dupixent users account for more cases than any other drug.
How Can Dupixent Cause a Parasitic Infection?
Dupixent suppresses immune system signals that fight parasitic infections. This can allow existing parasites to worsen or make new infections harder to eliminate.
What is the Downside of Dupixent?
The main downsides include a 4x increased cancer risk, injection site reactions, eye problems, herpes reactivation, severe allergic reactions, high cost, and need for ongoing treatment. Warning signs include new skin patches, swollen nodules, and unexplained weight loss.
Contact a Dupixent Lawyer For a Free Consultation
We take on cases nationwide and fight against drug manufacturers that prioritize profits over patient safety. We work on a contingency fee basis, which means there are no upfront costs and you owe nothing unless we secure the financial support and compensation you deserve.
Contact a Dupixent lawsuit attorney at 713-622-7271 or through our contact form.
Do not stop taking Dupixent without consulting your doctor.
There is never a fee unless we recover on your behalf.
Additionally, clients are not obligated to pay expenses if a recovery is not made.
